echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Ann Hematol: Management of Adverse Events in the Maintenance Treatment of Isazomib after Multiple Myeloma Transplantation

    Ann Hematol: Management of Adverse Events in the Maintenance Treatment of Isazomib after Multiple Myeloma Transplantation

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The TOURMALINE-MM phase 3 study (NCT02181413) showed that after autologous stem cell transplantation (ASCT) in patients with multiple myeloma , maintenance therapy with ixazomib had an improved progression-free survival rate compared with placebo.


    Stem cell management

    The researchers randomly assigned patients at a ratio of 3:2 to receive ixazomib (n = 395) or placebo (n = 261), respectively, and received treatment on days 1, 8 and 15 of the 28-day cycle for a period of approximately 2 years or until disease/toxicity progresses.


     

    The results showed that the incidence of grade ≥3 AEs in the ixazomib group (19%) was higher than that in the placebo group (5%), but the rate of discontinuation due to AEs was similar (7% vs.


    In summary, the results of this study indicate that ixazomib is an effective and tolerable option for maintenance therapy after ASCT.


     

    Original source:

     

    Martin Kaiser, et al.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.